Unicycive Therapeutics Inc
NASDAQ:UNCY
NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

  • LAST PRICE
    0.6889
  • TODAY'S CHANGE (%)
    0.0110 (1.6227%)
  • Bid / Lots
    0.6800/ 22
  • Ask / Lots
    0.6890/ 23
  • Open / Previous Close
    0.6859 / 0.6779
  • Day Range
    0.6600
    0.7400
  • 52 Week Range
    0.2020
    1.8180
  • Volume
    1,494,337

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

Charts

Price Comparison Graph. See accessible table below
Data delayed at least 15 minutes.

Biotechnology Industry Peers

CompanyMarket CapP/E Ratio (TTM)EPS Growth (5yr)
UNCY
Unicycive Therapeutics Inc
70.4M
-3.5x
---
XCUR
Exicure Inc
69.5M
-13.1x
---
MURA
Mural Oncology PLC
68.9M
-0.4x
---
VNRX
VolitionRX Ltd
64.6M
-1.9x
---
VTGN
Vistagen Therapeutics Inc
74.9M
-2.2x
---
CTOR
Citius Oncology Inc
67.0M
3.8x
---
As of 2024-11-29

Company Information

Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. Oxylanthanum Carbonate and UNI 494 were initially developed by and licensed to it from Spectrum Pharmaceuticals (Spectrum) and Sphaera Pharma, respectively.

Contact Information

Headquarters
4300 El Camino Real, Suite 210LOS ALTOS, CA, United States 94022
Phone
650-384-0642
Fax
302-655-5049

Executives

Chairman of the Board, President, Chief Executive Officer, Founder
Shalabh Gupta
Chief Financial Officer
John Townsend
Executive Vice President - Pharmaceutical and Business Operations
Pramod Gupta
Executive Vice President, Corporate Strategy
Doug Jermasek
Independent Director
Gaurav Aggarwal

Ratings

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

Reports

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals

Market Cap
$70.4M
Revenue (TTM)
$0.00
Shares Outstanding
103.8M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
2.35
EPS
$-0.20
Book Value
$-0.11
P/E Ratio
-3.5x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Calendar

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.